Jupiter Endovascular treats first patients with Vertex system in SPIRARE I study [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
The trial helps in the development of endovascular procedures using the company's Endoportal Control platform technology. The Vertex system, designed for acute PE treatment, offers a new level of control and precision in endovascular procedures. The first procedures were conducted at St John Paul II Hospital in Krakow, Poland, by a team of specialists, including professors Dr Grzysztof Bartus, Dr Grzegorz Kopec, and Dr Jakub Stepniewski. SPIRARE I is a prospective, multicentre, single-arm study that is designed to enrol patients with acute, intermediate-risk PE to treat with the Vertex system. The study is set to expand to the Medical University of Vienna, where professor Irene Lang will lead as the principal investigator. The study's endpoints will assess the procedural and clinical benefits of the Vertex system, focusing on safety, right heart function, and clinical improvement from the time of the procedure to 30 days after the procedure. Jupiter Endovascular CEO Carl Be
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $431.00 price target on the stock.MarketBeat
- Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript) [Seeking Alpha]Seeking Alpha
- Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics [Yahoo! Finance]Yahoo! Finance
- Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now? [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 8/1/24 - Miss
VRTX
Sec Filings
- 9/4/24 - Form 4
- 9/4/24 - Form 4
- 8/30/24 - Form 144
- VRTX's page on the SEC website